Evidence suggests mosquitos in Kenya have developed chemical resistance, KEMRI official says

NewsGuard 100/100 Score

Speaking at a national malaria forum in Nairobi on Monday, Charles Mbogo of the Kenya Medical Research Institute (KEMRI) presented new evidence showing that malaria-causing mosquitos in Kenya have developed resistance to the most common chemicals derived from pyrethroids and DDT, which "could be a major blow to the country's strategy to eradicate malaria by 2017," Nigeria's the Nation reports. "This new development comes at a time most parts of the country, especially the coastal region, have been recording a significant drop in malaria deaths," the newspaper writes.

"To determine how a chemical-tolerant mosquito will affect" the use of insecticide-treated bednets "as a control tool in the overall malaria reduction strategy, the World Health Organisation has commissioned a new study to be carried out in western Kenya, Benin and Cameroon," according to the Nation. "Treated bednets have been one of the most popular and heavily funded malaria control methods in Kenya, consuming up to 60 percent of funds from the U.S. President's Malaria Initiative and 40 percent of the Global Fund malaria package," the newspaper notes (Gathura, 10/10).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer